Scarica l'app Stockscreener
1.745
1.68%
-0.04
Precedente Chiudi:
$1.785
Aprire:
$1.76
Volume 24 ore:
110.63K
Relative Volume:
0.18
Capitalizzazione di mercato:
$72.18M
Reddito:
$90.50M
Utile/perdita netta:
$-54.00M
Rapporto P/E:
-1.3124
EPS:
-1.3296
Flusso di cassa netto:
$-32.64M
1 W Prestazione:
+21.88%
1M Prestazione:
+21.04%
6M Prestazione:
+3.85%
1 anno Prestazione:
-75.96%
Intervallo 1D:
$1.7341
$1.82
Intervallo di 1 settimana:
$1.45
$2.16
Portata 52W:
$1.31
$8.12
Pulmonx Corp Stock (LUNG) Company Profile
Nome
Pulmonx Corp
Settore
Industria
Telefono
650-364-0400
Indirizzo
700 CHESAPEAKE DRIVE, REDWOOD CITY
Compare LUNG vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LUNG
Pulmonx Corp
|
1.75 | 73.63M | 90.50M | -54.00M | -32.64M | -1.3296 |
|
ABT
Abbott Laboratories
|
110.09 | 192.10B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
342.26 | 137.25B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
88.89 | 115.41B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
68.85 | 103.81B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
84.50 | 49.82B | 6.07B | 1.06B | 1.34B | 1.8063 |
Pulmonx Corp Stock (LUNG) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-31 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2025-03-10 | Iniziato | D. Boral Capital | Buy |
| 2024-12-11 | Downgrade | Citigroup | Buy → Neutral |
| 2024-06-04 | Iniziato | Lake Street | Buy |
| 2024-02-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-09-05 | Iniziato | Craig Hallum | Buy |
| 2023-02-27 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-01-03 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-12-12 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-07-11 | Downgrade | Citigroup | Buy → Neutral |
| 2022-03-02 | Ripresa | BofA Securities | Neutral |
| 2021-12-08 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-04-01 | Iniziato | Citigroup | Buy |
| 2021-03-25 | Iniziato | Piper Sandler | Neutral |
| 2021-03-10 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-01-04 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-10-26 | Iniziato | BofA Securities | Buy |
| 2020-10-26 | Iniziato | Canaccord Genuity | Buy |
| 2020-10-26 | Iniziato | Morgan Stanley | Equal-Weight |
| 2020-10-26 | Iniziato | Stifel | Buy |
| 2020-10-26 | Iniziato | Wells Fargo | Equal Weight |
Mostra tutto
Pulmonx Corp Borsa (LUNG) Ultime notizie
Pulmonx 2025 10-K: Revenue $90.5M, EPS (Loss) $(1.33) - TradingView
Pulmonx Corporation (LUNG) Releases Q4 2025 Earnings: Revenue Down, Diluted Loss Per Share Widens - Quiver Quantitative
Published on: 2026-03-07 07:00:54 - baoquankhu1.vn
Pulmonx Corporation (NASDAQ:LUNG) Q4 2025 Earnings Call Transcript - Insider Monkey
Pulmonx (LUNG): Canaccord Genuity Maintains Buy Rating, Lowers P - GuruFocus
LUNG: Analyst Jason Kolbert Maintains 'Buy' Rating with $14 Targ - GuruFocus
Pulmonx (NASDAQ:LUNG) Given "Buy" Rating at D. Boral Capital - MarketBeat
Pulmonx Corporation Q4 2025 Earnings Call Summary - Yahoo Finance
Pulmonx Secures $60 Million Senior Secured Term Loan From Perceptive; $40 Million Drawn - TradingView
Pulmonx Corp (LUNG) Q4 2025 Earnings Call Highlights: Strategic - GuruFocus
Pulmonx (NASDAQ:LUNG) Insider Sells $11,056.76 in Stock - MarketBeat
Earnings call transcript: Pulmonx Q4 2025 EPS beats, revenue misses, stock dips - Investing.com South Africa
Pulmonx Q4 Earnings Call Highlights - Yahoo Finance
Pulmonx Corporation (LUNG) Posts Fourth Quarter Loss, Surpasses Revenue Projections - Bitget
Pulmonx closes $60M credit facility with Perceptive Advisors - Investing.com
Pulmonx closes $60 million credit facility with Perceptive - Investing.com
Pulmonx Corporation (LUNG) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Pulmonx (LUNG) Exceeds Q4 Revenue Expectations with Strategic Gr - GuruFocus
Pulmonx (LUNG) Projects 2026 Financial Outlook with Revenue and Margin Targets - GuruFocus
Pulmonx earnings beat by $0.14, revenue fell short of estimates - Investing.com
Pulmonx Corporation Reports Fourth Quarter and Full Year 2025 Financial Results, Highlights Transition and Strategic Focus for 2026 - Quiver Quantitative
Earnings Summary: Pulmonx Q4 - Benzinga
Lung device maker Pulmonx trims losses, guides 2026 sales to $90–92M - Stock Titan
Pulmonx Announces Closing of up to $60 Million Credit Facility - Yahoo Finance
Earnings Preview For Pulmonx - Benzinga
LUNG Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
LUNG Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
LUNG Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Pulmonx to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026 - Bitget
Analyst Jason Kolbert Maintains Buy Rating for Pulmonx (LUNG) at $14 Target | LUNG Stock News - GuruFocus
Pulmonx's (LUNG) "Buy" Rating Reiterated at D. Boral Capital - MarketBeat
Pulmonx Corporation to Announce Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026 - Quiver Quantitative
Pulmonx Stock Pops on Takeover Deal: Cash Exit or Hold Out? - AD HOC NEWS
Pulmonx Corporation (NASDAQ:LUNG) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Will Pulmonx Corporation stock outperform Dow Jones index2025 Biggest Moves & Daily Growth Stock Investment Tips - mfd.ru
Pulmonx Stock Under Pressure: Can A Niche Lung-Health Innovator Breathe New Life Into Its Shares? - AD HOC NEWS
Will Pulmonx Corporation stock beat EPS estimatesWeekly Risk Summary & Stock Portfolio Risk Control - mfd.ru
Pulmonx (LUNG) Expected to Announce Earnings on Wednesday - Defense World
Pulmonx Corporation (NASDAQ:LUNG) Not Doing Enough For Some Investors As Its Shares Slump 29% - simplywall.st
Merger Talk: Is Pulmonx Corporation a good ESG investment2025 Key Highlights & Free Community Consensus Stock Picks - baoquankhu1.vn
Pulmonx Aktie: Zahlen im Fokus - Börse Global
Pulmonx Q4 2025 Results: A Litmus Test for New Leadership - AD HOC NEWS
Sentiment Watch: Is Pulmonx Corporation a turnaround story2025 Technical Patterns & Weekly Top Gainers Alerts - baoquankhu1.vn
US Market Wrap: Can Cabaletta Bio Inc disrupt its industryJuly 2025 Outlook & Reliable Entry Point Alerts - baoquankhu1.vn
Analyzing Pulmonx (NASDAQ:LUNG) and Privia Health Group (NASDAQ:PRVA) - Defense World
Aug Rallies: How Pulmonx Corporation stock compares to growth peersJuly 2025 Gainers & Reliable Volume Spike Alerts - Bộ Nội Vụ
Why The Pulmonx LUNG Narrative Is Shifting After Target Cut And Leadership Return - Yahoo Finance
Is Pulmonx Corporation stock vulnerable to regulatory risks2025 Price Targets & Weekly High Potential Alerts - Улправда
How Pulmonx Corporation stock valuations compare to rivalsTrade Performance Summary & AI Driven Stock Price Forecasts - Улправда
Pulmonx Corporation (NASDAQ:LUNG) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Pulmonx Corporation (NASDAQ:LUNG) Given Consensus Rating of “Hold” by Brokerages - Defense World
Pulmonx Corp Azioni (LUNG) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.61%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):